GlassScriptPhysician profile
Aabha Oza
NPI 1225383680
$846.51
in general payments reported to CMS, 2019-2025
15 companies · $17.86 in 2025
The $17.86 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $99.00 · 2021: $280 · 2022: $122 · 2023: $93.29 · 2025: $17.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $265.01 | 2019-2022 | |
| Seagen INC. | $136.80 | 2020-2023 | Tukysa |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Pfizer INC. | $60.36 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $57.45 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $51.02 | 2021-2022 | |
| Asd Specialty Healthcare, LLC | $48.32 | 2019 | |
| Celgene Corporation | $21.13 | 2022 | |
| Astellas Pharma US INC | $17.91 | 2023 | Xtandi |
| Abbott Laboratories | $17.86 | 2025 | Proclaim |
| Acrotech Biopharma INC. | $17.85 | 2023 | Beleodaq |
| Pharmacyclics LLC, An Abbvie Company | $14.64 | 2023 | Imbruvica |
| Array Biopharma INC | $14.60 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aabha Oza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.